What is Friedreich Ataxia Drug Market?
Friedreich’s ataxia is an autosomal recessive genetic disease that causes progressive nervous system damage leads to difficulty walking, a loss of sensation in the arms and legs, and impaired speech. It is caused by a defect (mutation) in a gene labeled FXN, which carries the genetic code for a protein called frataxin. It is the most common form of hereditary ataxia in the United States, affecting about 1 in every 50,000 people. Today, there is no cure for Friedreich’s ataxia, but there are several interventions that may help to ease or manage symptoms and improve quality of life.
The market study is being classified by Type (Amitriptyline or Gabapentin, Muscle Relaxants and Antidepressants), by Application (Clinic, Hospital and Others) and major geographies with country level break-up.
Adverum Biotechnologies (United States), BioMarin Pharmaceutical Inc. (United States), Biovista Inc. (United States), Cardero Therapeutics Inc (United States), Catabasis Pharmaceuticals, Inc. (United States), Forward Pharma A/S (Denmark), Ixchel Pharma LLC (United States), Pfizer Inc (United States), ProQR Therapeutics NV (Netherlands), Reata Pharmaceuticals Inc. (United States), Retrotope Inc (United States) and Shire Plc (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are STATegics, Inc. (United States) and Voyager Therapeutics Inc (United States).
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Friedreich Ataxia Drug market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Friedreich Ataxia Drug market by Type, Application and Region.
On the basis of geography, the market of Friedreich Ataxia Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increased Prevalence of Friedreich's ataxia among People in the United States
- Development of New Diagnostic Centres and Hospitals
- Increased Awareness among People about Rare Diseases
- Non Availability of Complete Cure Treatment
- Increased Research and Development Investment
- Growth in the Healthcare Industry Worldwide
- Stringent Government Rules and Regulations
In July 2019, REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, has announced it entered into a license agreement with Pfizer Inc.
Key Target AudienceFriedreich Ataxia Drug Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies, Research Professionals and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase